Bart G. Verheggen
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands.
Journal: Journal of medical economics
Published: November 09, 2021
Corrigendum: Internet Blogs, Polar Bears, and Climate-Change Denial by Proxy.
Journal: Bioscience
Published: April 18, 2018
Internet Blogs, Polar Bears, and Climate-Change Denial by Proxy.
Journal: Bioscience
Published: April 18, 2018
Corrigendum: Internet Blogs, Polar Bears, and Climate-Change Denial by Proxy.
Journal: Neurosurgery
Published: April 03, 2018
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Journal: Journal of medical economics
Published: June 17, 2016
Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments.
Journal: Current medical research and opinion
Published: January 21, 2016
Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013.
Journal: Current medical research and opinion
Published: October 17, 2015
Reply to comment on "Scientists' views about attribution of global warming".
Journal: Environmental science & technology
Published: November 19, 2014
The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Last Updated: 09/26/2026